Neurology › Alzheimer’s Disease

AI-Driven Benefit-Risk Analysis for Alzheimer’s Disease

Alzheimer’s disease BRA centers on anti-amyloid antibody therapies with novel ARIA monitoring requirements, ApoE4 genotype-based risk stratification, and the complex balance between modest cognitive slowing against significant safety signals. ArcaScience delivers genotype-aware safety profiling across lecanemab, donanemab, and emerging disease-modifying therapies.

See Platform Request Demo

55,000,000+

Dementia patients globally

600+

AD clinical trials analyzed

$13B

Global AD therapeutics market

Emerging

Novel disease-modifying therapy class

Disease Overview

Why Alzheimer’s Disease Demands Specialized BRA

The advent of anti-amyloid antibodies has introduced an entirely novel safety paradigm in neurology. ARIA (Amyloid-Related Imaging Abnormalities) requires MRI-based monitoring, genotype-driven risk assessment, and careful weighing of modest cognitive slowing against serious brain edema and microhemorrhage risks—challenges that demand purpose-built benefit-risk frameworks.

ARIA-E & ARIA-H Monitoring

Anti-amyloid antibodies including lecanemab and donanemab cause ARIA-E (vasogenic edema) in 12–35% of patients and ARIA-H (microhemorrhages and superficial siderosis) in 14–20%. Most ARIA events are radiographic and asymptomatic, but symptomatic ARIA can include headache, confusion, visual disturbances, and in rare cases, serious cerebral macrohemorrhage. BRA must integrate MRI monitoring frequency, dose modification protocols, and clinical significance stratification.

ApoE4 Genotype Risk Stratification

ApoE4 homozygotes face dramatically elevated ARIA risk—up to 3–4 times higher than non-carriers—and more severe presentations including symptomatic ARIA-E and macrohemorrhage. The Clarity AD and TRAILBLAZER-ALZ 2 trials revealed that ApoE4 status fundamentally alters the benefit-risk equation, leading to label restrictions and mandatory genotyping requirements. BRA must model risk-benefit separately by ApoE4 zygosity (homozygous, heterozygous, non-carrier).

Cognitive Benefit vs. Safety Tradeoff

Anti-amyloid therapies demonstrate statistically significant but clinically modest cognitive slowing (27–35% reduction in decline on CDR-SB). Whether this magnitude of benefit justifies ARIA risks, infusion burden, and cost remains the central BRA question. The platform models clinical meaningfulness thresholds, minimal clinically important differences, and patient and caregiver preference weighting to support transparent benefit-risk communication.

Platform Capabilities

How ArcaScience Addresses Alzheimer’s Disease BRA

Our platform is configured with Alzheimer’s-specific ARIA detection models, ApoE4 genotype-stratified risk analytics, and regulatory templates aligned with the FDA’s accelerated approval and confirmatory trial monitoring requirements.

Data Intelligence

Alzheimer’s Data Coverage

600+ AD clinical trials including Clarity AD, TRAILBLAZER-ALZ 2, EMERGE/ENGAGE, AHEAD, and DIAN-TU datasets. ARIA event data covering edema severity grading, microhemorrhage counts, superficial siderosis progression, and symptomatic vs. radiographic-only events. ApoE4 genotype-stratified safety data from all major anti-amyloid programs.

Explore Data Engine →

Decision Intelligence

ARIA Risk Prediction Models

AI models for ARIA onset prediction based on ApoE4 status, baseline MRI findings, and treatment duration. Genotype-stratified benefit-risk modeling across ApoE4 homozygotes, heterozygotes, and non-carriers. CDR-SB and ADAS-Cog cognitive endpoint modeling with minimal clinically important difference thresholds. BRAT framework application with AD-specific regulatory precedent from PCNS advisory committee deliberations.

Explore AI Models →

Automated Outputs

Neurology Regulatory Outputs

PSURs with ARIA deep-dives by genotype and severity grade, REMS-aligned monitoring protocols with MRI scheduling guidance, CTD 2.5 with CDR-SB, ADAS-Cog, and amyloid PET biomarker endpoint integration, and HEOR reports supporting payer submissions with quality-adjusted life year modeling for anti-amyloid therapies.

Explore Outputs →

Alzheimer’s Disease Intelligence

Platform Performance in Alzheimer’s Disease

4,200,000,000+

AD adverse event data points including ARIA

70%

Faster ARIA signal characterization

ApoE4 genotype strata modeled

Anti-amyloid program submissions supported

Case Evidence — Alzheimer’s Disease

ARIA Monitoring Program for Anti-Amyloid Therapy Launch

Challenge

A large pharma company preparing for commercial launch of an anti-amyloid antibody needed to design a comprehensive post-marketing ARIA monitoring program. The FDA required detailed ARIA surveillance with genotype-stratified reporting, and the company needed real-time benefit-risk updates to support REMS compliance and payer negotiations demonstrating clinical value in the ApoE4-stratified population.

Result

ArcaScience deployed ARIA-specific detection models trained on anti-amyloid clinical trial MRI data, enabling automated ARIA severity grading and ApoE4-stratified incidence tracking. The platform reduced ARIA case adjudication time by 65% and provided real-time genotype-specific benefit-risk dashboards that supported both FDA post-marketing commitments and NICE/G-BA health technology assessments for reimbursement.

65%

Faster ARIA case adjudication

More granular genotype stratification

View All Case Studies →

The ARIA monitoring capabilities ArcaScience built for our anti-amyloid program were essential for our launch strategy. Being able to track ARIA by ApoE4 genotype in real time gave us the evidence we needed for our REMS program and gave payers confidence in the safety monitoring infrastructure supporting our therapy.

Head of Neuroscience Safety & Pharmacovigilance

Global Pharma Company

Frequently Asked Questions

Alzheimer’s Disease Benefit-Risk Analysis

Our platform maintains separate risk models for ApoE4 homozygotes (e4/e4), heterozygotes (e4/e3 or e4/e2), and non-carriers, reflecting the 3–4 fold difference in ARIA incidence across these groups. For homozygotes, where ARIA-E rates can exceed 35% and serious symptomatic events are substantially more common, the benefit-risk equation is modeled separately with adjusted benefit thresholds. The platform also incorporates emerging data on ApoE4-stratified efficacy, as some trials suggest differential cognitive benefit by genotype, which further complicates the risk-benefit calculus for these patients.

ArcaScience models the cognitive benefit using CDR-SB, ADAS-Cog 14, and ADCS-MCI-ADL endpoints with explicit minimal clinically important difference (MCID) thresholds. The platform weighs demonstrated cognitive slowing (typically 0.45–0.67 CDR-SB points at 18 months) against ARIA incidence, severity, and clinical significance. We incorporate patient and caregiver preference data from discrete choice experiments and conjoint analyses to model acceptable risk thresholds, recognizing that patient-perceived value of even modest cognitive preservation may exceed what clinical metrics alone suggest.

Yes. Our BRA framework extends beyond traditional patient-centric safety and efficacy to incorporate caregiver burden as a benefit dimension. Anti-amyloid therapies require biweekly infusions and serial MRI monitoring, imposing significant logistical burden on caregivers. The platform models treatment burden alongside ARIA monitoring requirements, infusion center accessibility, and the caregiver quality-of-life impact of cognitive benefit versus treatment demands. This broader perspective is increasingly required by HTA bodies evaluating real-world value of AD disease-modifying therapies.

ArcaScience provides purpose-built tools for the unique regulatory landscape of anti-amyloid therapies, many of which received accelerated or traditional approval with extensive post-marketing commitments. The platform tracks confirmatory trial endpoints, generates post-marketing ARIA surveillance reports aligned with REMS requirements, monitors real-world ARIA incidence against clinical trial benchmarks, and provides early signal detection for emerging safety concerns in broader commercial populations including patients with comorbidities excluded from registration trials. The platform also supports PDUFA commitment tracking and PMR/PMC compliance reporting.

Yes. Our platform provides cross-trial comparative analyses of lecanemab, donanemab, and aducanumab using network meta-analytic approaches and indirect treatment comparison methodologies. We compare ARIA incidence and severity profiles, cognitive efficacy endpoints, amyloid clearance rates, and dosing regimen burden across agents. The platform accounts for trial design differences, population heterogeneity, and endpoint measurement variability to produce clinically meaningful comparative BRA outputs that support formulary positioning, clinical guideline development, and regulatory advisory committee preparation.

See ArcaScience Applied to Alzheimer’s Disease

Request a demonstration of ArcaScience’s platform configured for Alzheimer’s disease benefit-risk analysis. Our neuroscience scientists will walk through ARIA monitoring models, ApoE4-stratified risk analytics, and regulatory output examples tailored to anti-amyloid therapy submissions.

Request Alzheimer’s Briefing Explore the Platform →